Navigation Links
Helix BioPharma Corp. Announces Positive Phase II Clinical Results,with its Topical Interferon Alpha-2b

Helix BioPharma Corp.

AURORA, ON, March 30, 2007 /PRNewswire-FirstCall/ - Helix today announced positive results from its phase II clinical study of its Topical Interferon Alpha-2b in women with human papilloma virus (HPV) induced low-grade cervical lesions.

The study showed a clinically efficacious response to treatment in nearly half of the treated patients. In addition, the product demonstrated an excellent safety profile, with no significant local intolerance or drug-related serious adverse event observations.

"Treated patients responded well, both in terms of efficacy and safety to this new investigational therapeutic," said Prof. Dr. med. Achim Schneider M.P.H., a world expert in the field of cervical cancer and Director of the Department of Gynaecology at the Charite University Hospital in Berlin. "Helix's product shows real promise as a practical and effective pharmaceutical means of preventing cervical cancer development in women presenting with HPV-induced cervical lesions", continued Prof. Schneider.

About the Clinical Study

A total of 41 women with cytologically confirmed, HPV-induced low-grade squamous intraepithelial lesions (LSIL) of the cervix were studied across four sites in Germany. Twenty women received Topical Interferon Alpha-2b, self-administered intravaginally three times per week for a period of 6 weeks with a follow-up evaluation at 12 weeks, compared with 21 separately studied women who received no treatment whatsoever over the same study period.

The primary endpoint and main outcome for both groups was the Pap-response rate defined as the proportion of patients with resolution of their abnormal Pap smear LSIL cytology to normal during the 12 week study duration. Pap smear normalization was considered to occur if the patient's Pap smear improved to group II or better from any of Pap smear groups IIW through IIID as per the common European stan
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Helix BioMedix to Discuss Potential of Its Proprietary Peptides at the BIO International Convention
2. Helix Biopharma to Present L-DOS47 Lung Cancer Research Findings at the Fourth International Conference on Tumor Microenvironment in Florence, Italy
3. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
4. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
5. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
6. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
7. Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory Drugs
8. PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week
9. AVI BioPharma Reports Positive Pre-Clinical Influenza Data
10. CeNeRx BioPharma Announces Positive Phase I Results in First Human Trial of Third Generation RIMA Antidepressant
11. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
Post Your Comments:
(Date:3/27/2015)... , March 27, 2015 BioCorRx, Inc. ( ... Santa Ana, California is a healthcare solutions organization, ... is estimated at $22 billion in the U.S. alone. The ... of FDA-approved Naltrexone in a specially compounded form for outpatient ... Australia and New Zealand ) ...
(Date:3/27/2015)... -- Object recognition technology has a unique and powerful ... VelaSense ® mobile platform incorporates applications ... and fulfilling lives. VelaSense ® will now incorporate ... objects from a one million object database, that is ... for personal use. Visus Technology ...
(Date:3/27/2015)... -- Biopharmaceutical Industry Leads Manufacturing Sector in R&D ... top as the country,s manufacturing leader in innovation and ... According to the  analysis , the industry had the ... decade, accounting for 27 percent of average annual R&D ... Video on Medicare Part D - Medicare Part ...
Breaking Medicine Technology:Small Cap IR Correction -- BioCorRx Inc. Positions Itself Through Strategic Partnerships To Gain Market Share Of The $22 Billion Substance Abuse Treatment Market In The U.S. 2VelaSense Object Recognition Technology for the Blind was unveiled at Baruch College's CCVIP 8th Annual Conference 2Week in Review: The Latest from PhRMA 2
... Analyses of School and Daycare Study Outcomes ... for,Community at Large, TORONTO, May 08, 2007 ... showing that use of FluMist(R),(Influenza Virus Vaccine ... help reduce the burden of seasonal influenza. ...
... - Regeneron,Pharmaceuticals, Inc. (Nasdaq: REGN) today announced positive,results ... the,neovascular form of age-related macular degeneration (wet AMD) ... this,week at the annual meeting of the Association ... reported at the meeting,from a pre-planned interim analysis ...
Cached Medicine Technology:Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 2Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 3Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 4Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 5Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 6Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 7Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 8VEGF Trap-Eye Phase 2 Wet AMD Results Reported at ARVO Annual,Meeting 2VEGF Trap-Eye Phase 2 Wet AMD Results Reported at ARVO Annual,Meeting 3VEGF Trap-Eye Phase 2 Wet AMD Results Reported at ARVO Annual,Meeting 4VEGF Trap-Eye Phase 2 Wet AMD Results Reported at ARVO Annual,Meeting 5
(Date:3/28/2015)... (PRWEB) March 28, 2015 With ... in the fields of osteoporosis, osteoarthritis and musculoskeletal ... Osteoporosis, it may be the first time in ... research forum that the hot-button topic is an ... on the well-accepted scientific principles of Wolff’s law, ...
(Date:3/28/2015)... The California-based leading wig brand UniWigs has prepared a ... during the Easter Holidays from today until April 6th. ... Fools’ Day. , As the winter fades and spring ... Festival, with religious origins to countries in Europe and ... The best wig provider, UniWigs, would like to offer ...
(Date:3/28/2015)... 28, 2015 India Network visitor ... made available to all visitors who purchase the plan ... members are encouraged to purchase the insurance program as ... of proper coverage for pre-existing medical conditions. Parents and ... two medical conditions with serious consequences to their health. ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 Centurion Service Group ... auction on Thursday, April 2 at their Las Vegas warehouse, ... NV 89081. The sale, which consists of equipment from hospitals ... promptly at 9 a.m. PDT. , Buyers will find ... surgery equipment. “We are a one-stop-shop,” said Erik Tivin, CEO ...
(Date:3/28/2015)... Vegas, NV (PRWEB) March 28, 2015 ... experiences re-injury, according to research presented today at the ... Specialty Day. The study examined the long term success ... , “We examined survey data from 242 patients ... lead author Justin P. Roe, MBBS, FRACS, from North ...
Breaking Medicine News(10 mins):Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:UniWigs Is Sending Out Mysterious Gifts During the Easter Holidays 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3Health News:Medical Equipment Auction to Take Place in North Las Vegas 2Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2
... the world sparking many lifestyle ailments like type 2 diabetes, ... ordered. A pill// is soon gaining ground for preventing type ... the pill once or twice daily, enhances the body’s receptive ... diabetes. ,The pill, named as rosiglitazone, marketed ...
... of the European Association for the Study of Diabetes ... antidiabetic medication, demonstrated significant cardiovascular benefits such as reducing ... coronary syndrome in patients with type 2 diabetes. ... premature death in patients with diabetes. An estimated 171 ...
... during cataract surgery have led to a new—and controversial—surgical ... farsightedness that typically develops in middle age. But a ... this operation to weigh its risks, as well as ... lenses, which enable people to see objects at varying ...
... Medicine (ABIM)and the American Society of Hematology (ASHTM) ... evaluation tools for// blood specialists. ... Improvement Module (PIM), which is a web-based tool ... requirement for recertification for ABIM. Participants in ABIM's ...
... 1199NW has said that it supports the "Marty Smith" ... a partner when// they visit high-risk patients. Marty Smith ... of Larry Clark, a child rapist whose mother had ... his medications. ,Smith's case proves that mental ...
... and and Amylin Pharmaceuticals has announced that exenatide is ... iphasic insulin // aspart 30/70 (NovoMix by NovoNordisk). This finding ... This is indeed a boon to people suffering type 2 ... oral diabetes drugs. , ,The study, which ...
Cached Medicine News:Health News:ACTOS Linked to Several Cardiovascular Benefits 2Health News:ACTOS Linked to Several Cardiovascular Benefits 3Health News:ACTOS Linked to Several Cardiovascular Benefits 4Health News:Improved Patient Care from Blood Specialists with New Web based Tool 2
... style offers men and women updated shapes and ... feature modern shapes and easy to wear deigns ... a casual look with combinations of metal fronts ... custom Hush Puppies nosepads for added comfort and ...
... name Silhouette stands for the power ... began in 1964 with just one ... a novel, pioneering approach: eyewear was ... implement to improve faulty vision; rather, ...
... Eyewear Collection reflects the ... elegance, refinement and comfort ... dedication to quality and ... of the Lacoste brand, ...
... Charmant's Pure Titanium Collection is the ... frames, consisting of 100% pure titanium ... hypoallergenic composition and superior corrosion resistance. ... and durability delivers a collection that ...
Medicine Products: